Loading
A phase 3 trial of Filgrastim and Plerixafor in Non-Hodgkin lymphoma, run by Sanofi, completed.
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation is a phase 3 interventional study registered as NCT01767714 by Sanofi, with 100 participants recorded, started 2013-04 and reaching its primary completion in 2014-11. Interventions recorded: Granulocyte-colony stimulating factor (G-CSF), Plerixafor, Placebo. Conditions recorded: Non-Hodgkin's Lymphoma.
Linked to the drug Plerixafor because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Shares Plerixafor, Sanofi and the tag pipeline.
Shares Plerixafor, Filgrastim (G-CSF) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.